| Item | Cat. No. | Application | Isotype |
| Anti-CD41 [7E3 (Abciximab)] (MABL-3689) | MABL-3689 | Block, FC | Engineer antibody |
| Anti-CD49B [GBR500 (Vatelizumab, TMC-2206)] (MABL-3690) | MABL-3690 | therapeutic, Block, ELISA, FC | Engineer antibody |
| Anti-CD52 [Alemtuzumab (Campath-1H)] (MABL-3691) | MABL-3691 | Cytotoxicity Assay, IHC-P, in vivo, WB, ELISA, FC, IHC-Fr | Engineer antibody |
| Anti-CD52 [YTH 34.5-G2b (Campath-1G)] (MABL-3692) | MABL-3692 | Cytotoxicity Assay, IHC-P, in vivo, WB, ELISA, FC, IHC-Fr | Engineer antibody |
| Anti-CD80 [IDEC-114 (Galiximab)] (MABL-3693) | MABL-3693 | IP, modulate, WB, Block, ELISA, FC, IHC | Engineer antibody |
| Anti-CD98 [EP3-1] (MABL-3694) | MABL-3694 | Activate, IP, IF | Engineer antibody |
| Anti-DR5 [PRO95780 (Drozitumab)] (MABL-3695) | MABL-3695 | agonist, functional/therapeutic, immunoblot, IP, ELISA, IF | Engineer antibody |
| Anti-EGFR [2F8 (Zalutumumab; HuMax-EGFR)] (MABL-3696) | MABL-3696 | WB, ELISA, FC | Engineer antibody |
| Anti-EGFR [C225 (Cetuximab)] (MABL-3697) | MABL-3697 | Block, FC | Engineer antibody |
| Anti-EGFR [Matuzumab] (MABL-3698) | MABL-3698 | antagonist, WB, Block, ELISA, FC, IF | Engineer antibody |
| Anti-EGFR domain III [h-R3 (Nimotuzumab)] (MABL-3699) | MABL-3699 | Block, FC, IHC | Engineer antibody |
| Anti-erbB-2 (Her-2/neu) [4D5-8 (trastuzumab)] (MABL-3700) | MABL-3700 | ELISA, FC, IHC | Engineer antibody |
| Anti-FAP alpha [BIBH1 (Sibrotuzumab, huF19)] (MABL-3701) | MABL-3701 | ELISA, FC, IHC | Engineer antibody |
| Anti-Fas [R-125224] (MABL-3702) | MABL-3702 | Activate, ELISA, FC, Imaging | Engineer antibody |
| Anti-FOLR1 [Farletuzumab (MORAb-003; M3)] (MABL-3703) | MABL-3703 | antagonist, functional assay, in vivo, inhibition, neutralizing, ELISA, IHC | Engineer antibody |
| Anti-IgE [huMaE11 (Omalizumab)] (MABL-3704) | MABL-3704 | crystallization, Block, ELISA | Engineer antibody |
| Anti-IL-12/23 [ABT-874 (Briakinumab)] (MABL-3705) | MABL-3705 | Block | Engineer antibody |
| Anti-IL-20 [h15D2 (Fletikumab)] (MABL-3706) | MABL-3706 | inhibit, neutralize, therapeutic, WB, ELISA | Engineer antibody |
| Anti-IL-2R [Daclizumab] (MABL-3707) | MABL-3707 | Block, FC | Engineer antibody |
| Anti-IL-2R alpha [Basiliximab] (MABL-3708) | MABL-3708 | WB, Block, FC, IF, IHC | Engineer antibody |
联系我们
Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有
地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话:15339069646 邮箱:info@mabioway.cn
